{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:56:30Z","timestamp":1764752190715,"version":"3.46.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Augsburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Drug-induced liver injury (DILI) is a relevant adverse event of tuberculosis treatment (TBT) especially in sub-Saharan Africa, but data remains limited. Genetic hepatic transport proteins polymorphisms (HTPP) are potential contributors. This study aimed to assess frequency and timing of DILI, identify risk factors, and explore the association of HTPP with DILI risk in Ethiopian TBT-patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective study, 424 confirmed tuberculosis patients in Ethiopian were recruited before initiation of TBT. Liver function tests were conducted during the first 8 weeks of treatment. Baseline evaluations included sociodemographic-, lifestyle- and clinical data including testing for viral co-infections, and HTPP as well as liver stiffness measurement by transient elastography (TE). Multivariable logistic regression, Cox proportional hazards models, and Fine and Gray competing risks analyses were employed for statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cumulative DILI incidence was 16.0% with 4.2% classified as severe occurring most commonly within the first two weeks. Urban residence (OR 2.00, 95% CI 1.03\u20133.84; HR 1.80, 95% CI 1.00\u20133.22) was associated with increased DILI risk. In the competing risks model, urban residence (sHR 6.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010) and pathologic TE (sHR 5.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) predicted severe DILI. The investigated HTPPs were not significantly associated with DILI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DILI is a common early complication of TBT in Ethiopian patients. Assessment of sociodemographic factors and TE before TBT may help identify high-risk individuals and offers a pragmatic approach for DILI management in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02632-7","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:51:10Z","timestamp":1756997470000},"page":"2833-2846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic and clinical risk factors for anti-tuberculosis drug-induced liver injury: insights from a prospective cohort study in central Ethiopia"],"prefix":"10.1007","volume":"53","author":[{"given":"Caroline","family":"Klindt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Behnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten Alexandra","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christian","family":"Orth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frieder","family":"Pf\u00e4fflin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Million Getachew","family":"Mesfun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tafese Beyene","family":"Tufa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Feldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2632_CR1","unstructured":"Organization WH. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (accessed 23.11.2024)."},{"key":"2632_CR2","unstructured":"Organization GWH. Global tuberculosis report 2020. 2020 Global TB Report https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf (accessed 04.07.2021)."},{"key":"2632_CR3","unstructured":"G. P. o. T. a. L. H. (GTB), Global tuberculosis report 2024. (no. 14th May, 2025). 2024."},{"key":"2632_CR4","doi-asserted-by":"publisher","unstructured":"L\u00f6nnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants, (in eng). Soc Sci Med. Jun 2009;68(12):2240\u20136. https:\/\/doi.org\/10.1016\/j.socscimed.2009.03.041.","DOI":"10.1016\/j.socscimed.2009.03.041"},{"key":"2632_CR5","unstructured":"M. o. H. Federal Democratic Republic of Ethiopia. National guidelines for TB, DR-TB and Leprosy in Ethiopia Sixth Edition. https:\/\/www.afro.who.int\/sites\/default\/files\/2019-04\/Ethiopia-National%20guidelines%20for%20TB%2C%20DR-TB%20and%20Leprosy%20in%20Ethiopia%20-%20Sixth%20Edition.pdf (accessed."},{"key":"2632_CR6","doi-asserted-by":"publisher","unstructured":"Amirneni S, Haep N, Gad MA, Soto-Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis, (in eng), World J Gastroenterol, vol. 26, no. 47, pp. 7470\u20137484, Dec 21 2020, https:\/\/doi.org\/10.3748\/wjg.v26.i47.7470","DOI":"10.3748\/wjg.v26.i47.7470"},{"key":"2632_CR7","doi-asserted-by":"publisher","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review, (in eng). J Gastroenterol Hepatol. Feb 2008;23(2):192\u2013202. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.05207.x.","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"2632_CR8","doi-asserted-by":"publisher","unstructured":"Ramappa V, Aithal GP. Hepatotoxicity related to Anti-tuberculosis drugs: mechanisms and management, (in eng). J Clin Exp Hepatol. Mar 2013;3(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jceh.2012.12.001.","DOI":"10.1016\/j.jceh.2012.12.001"},{"key":"2632_CR9","doi-asserted-by":"publisher","unstructured":"Saukkonen JJ et al. An official ATS statement: hepatotoxicity of antituberculosis therapy, (in eng), Am J Respir Crit Care Med, vol. 174, no. 8, pp. 935\u2009\u2013\u200952, Oct 15 2006, https:\/\/doi.org\/10.1164\/rccm.200510-1666ST","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"2632_CR10","doi-asserted-by":"publisher","unstructured":"Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from india: causes, outcome, prognosis, and predictors of mortality, (in eng). Am J Gastroenterol. Nov 2010;105(11):2396\u2013404. https:\/\/doi.org\/10.1038\/ajg.2010.287.","DOI":"10.1038\/ajg.2010.287"},{"key":"2632_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HMER.S290542","volume":"13","author":"Y Molla","year":"2021","unstructured":"Molla Y, Wubetu M, Dessie B. Anti-Tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, ethiopia, (in eng). Hepat Med. 2021;13:1\u20138. https:\/\/doi.org\/10.2147\/HMER.S290542.","journal-title":"Hepat Med"},{"issue":"11","key":"2632_CR12","doi-asserted-by":"publisher","first-page":"e0241346","DOI":"10.1371\/journal.pone.0241346","volume":"15","author":"LK Gezahegn","year":"2020","unstructured":"Gezahegn LK, Argaw E, Assefa B, Geberesilassie A, Hagazi M. Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North ethiopia: A cross-sectional study, (in eng). PLoS ONE. 2020;15(11):e0241346. https:\/\/doi.org\/10.1371\/journal.pone.0241346.","journal-title":"PLoS ONE"},{"key":"2632_CR13","doi-asserted-by":"publisher","unstructured":"Wondwossen Abera W, Cheneke, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study, (in eng), Int J Mycobacteriol, vol. 5, no. 1, pp. 14\u201320, Mar 2016, https:\/\/doi.org\/10.1016\/j.ijmyco.2015.10.002","DOI":"10.1016\/j.ijmyco.2015.10.002"},{"key":"2632_CR14","doi-asserted-by":"publisher","unstructured":"Schutz C et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa, (in eng), S Afr Med J, vol. 102, no. 6, pp. 506\u2009\u2013\u200911, Mar 02 2012, https:\/\/doi.org\/10.7196\/samj.5650","DOI":"10.7196\/samj.5650"},{"key":"2632_CR15","doi-asserted-by":"publisher","unstructured":"Akkahadsee P, Sawangjit R, Phumart P, Chaiyakunapruk N, Sakloetsakun D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. (in eng) Sci Rep. Nov 14 2023;13(1):19880. https:\/\/doi.org\/10.1038\/s41598-023-46565-3.","DOI":"10.1038\/s41598-023-46565-3"},{"issue":"2","key":"2632_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jhep.2024.04.006","volume":"81","author":"HJ Verkade","year":"2024","unstructured":"Verkade HJ, et al. EASL clinical practice guidelines on genetic cholestatic liver diseases. J Hepatol. 2024;81(2):303\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.006.","journal-title":"J Hepatol"},{"key":"2632_CR17","doi-asserted-by":"publisher","unstructured":"Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis, (in eng), BMC Infect Dis, vol. 16, no. 1, p. 761, Dec 19 2016, https:\/\/doi.org\/10.1186\/s12879-016-2090-1","DOI":"10.1186\/s12879-016-2090-1"},{"key":"2632_CR18","first-page":"1689","volume":"53","author":"EPH I. a","year":"2019","unstructured":"I. a. EPH, ICF. Ethiopia mini demographic and health survey 2019: key indicators. J Chem Inf Model. 2019;53:1689\u201399.","journal-title":"J Chem Inf Model"},{"key":"2632_CR19","doi-asserted-by":"publisher","unstructured":"Yimer G et al. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients, (in eng), PLoS One, vol. 3, no. 3, p. e1809, Mar 19 2008, https:\/\/doi.org\/10.1371\/journal.pone.0001809","DOI":"10.1371\/journal.pone.0001809"},{"key":"2632_CR20","doi-asserted-by":"publisher","unstructured":"Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia, (in eng), BMC Res Notes, vol. 13, no. 1, p. 2, Jan 02 2020, https:\/\/doi.org\/10.1186\/s13104-019-4872-1","DOI":"10.1186\/s13104-019-4872-1"},{"key":"2632_CR21","doi-asserted-by":"publisher","unstructured":"Kim B, et al. HLA-DPB1*05:01 and HLA-A*11:01 is associated with adverse drug reactions to isoniazid and Rifampin for treatment of latent tuberculosis infection in South korea, (in eng). J Clin Med. Jun 18 2024;13(12). https:\/\/doi.org\/10.3390\/jcm13123563.","DOI":"10.3390\/jcm13123563"},{"key":"2632_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fphar.2017.00090","volume":"8","author":"Z Petros","year":"2017","unstructured":"Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E. HLA-B*57 allele is associated with concomitant Anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians, (in eng). Front Pharmacol. 2017;8:90. https:\/\/doi.org\/10.3389\/fphar.2017.00090.","journal-title":"Front Pharmacol"},{"key":"2632_CR23","doi-asserted-by":"publisher","unstructured":"Saran C, Brouwer KLR. Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity, (in eng), Toxicol Pathol, vol. 51, no. 7\u20138, pp. 405\u2013413, Oct 2023, https:\/\/doi.org\/10.1177\/01926233231212255","DOI":"10.1177\/01926233231212255"},{"issue":"9","key":"2632_CR24","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1124\/dmd.105.008854","volume":"34","author":"T Lang","year":"2006","unstructured":"Lang T, et al. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (<\u2009em\u2009>\u2009ABCB4) and bile salt export pump (<\u2009em\u2009>\u2009ABCB11). Drug Metab Dispos. 2006;34(9):1582\u201399. https:\/\/doi.org\/10.1124\/dmd.105.008854.","journal-title":"Drug Metab Dispos"},{"key":"2632_CR25","doi-asserted-by":"publisher","unstructured":"Guo YX et al. The Inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid\/rifampicin-induced hepatotoxicity. Toxicol Mech Methods, 25, 5, pp. 382\u20137, 2015\/06\/13 2015, https:\/\/doi.org\/10.3109\/15376516.2015.1033074","DOI":"10.3109\/15376516.2015.1033074"},{"issue":"3","key":"2632_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jhep.2020.04.036","volume":"73","author":"AF St\u00e4ttermayer","year":"2020","unstructured":"St\u00e4ttermayer AF, Halilbasic E, Wrba F, Ferenci P, Trauner M. Variants in <\u2009em\u2009>\u2009ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol. 2020;73(3):651\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.036.","journal-title":"J Hepatol"},{"key":"2632_CR27","doi-asserted-by":"publisher","unstructured":"Yimer G et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients, (in eng), PLoS One, vol. 6, no. 12, p. e27810, 2011, https:\/\/doi.org\/10.1371\/journal.pone.0027810","DOI":"10.1371\/journal.pone.0027810"},{"key":"2632_CR28","doi-asserted-by":"publisher","unstructured":"Friedrich-Rust M et al. Apr., Performance of transient elastography for the staging of liver fibrosis: a meta-analysis, (in eng), Gastroenterology, vol. 134, no. 4, pp. 960\u2009\u2013\u200974, 2008, https:\/\/doi.org\/10.1053\/j.gastro.2008.01.034","DOI":"10.1053\/j.gastro.2008.01.034"},{"key":"2632_CR29","doi-asserted-by":"publisher","unstructured":"B\u00e9nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting, (in eng), J Hepatol, vol. 11, no. 2, pp. 272-6, Sep 1990, https:\/\/doi.org\/10.1016\/0168-8278(90)90124-a","DOI":"10.1016\/0168-8278(90)90124-a"},{"key":"2632_CR30","doi-asserted-by":"publisher","unstructured":"Kubitz R, Brinkmeyer C, Sagir A, Herebian D, H\u00e4ussinger D. Genetic variants of the bile salt export pump: inducers and modifiers of liver diseases, (in eng), Dig Dis, vol. 29, no. 1, pp. 89\u201392, 2011, https:\/\/doi.org\/10.1159\/000324140","DOI":"10.1159\/000324140"},{"key":"2632_CR31","doi-asserted-by":"publisher","unstructured":"Aithal GP et al. Case definition and phenotype standardization in drug-induced liver injury, (in eng), Clin Pharmacol Ther, vol. 89, no. 6, pp. 806\u2009\u2013\u200915, Jun 2011, https:\/\/doi.org\/10.1038\/clpt.2011.58","DOI":"10.1038\/clpt.2011.58"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02632-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:53:04Z","timestamp":1764751984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02632-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02632-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"CK has received non-financial benefits from Madrigal and Ipsen Pharma. AF has received speaker honoraria from AstraZeneca, Gilead Sciences, GlaxoSmithKline, Pfizer Inc., and ViiV Healthcare and consultation fees from AstraZeneca, Gilead Sciences, Pfizer Inc., Shionogi and ViiV Healthcare. The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and declarations"}}]}}